scholarly journals Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells

1999 ◽  
Vol 20 (5) ◽  
pp. 757-763 ◽  
Author(s):  
Marc E. Surette ◽  
Alfred N. Fonteh ◽  
Chantale Bernatchez ◽  
Floyd H. Chilton
Keyword(s):  
FEBS Open Bio ◽  
2018 ◽  
Vol 8 (10) ◽  
pp. 1703-1710 ◽  
Author(s):  
Xian‐Yang Qin ◽  
Jun Lu ◽  
Muyi Cai ◽  
Soichi Kojima

1994 ◽  
Vol 212 (2) ◽  
pp. 262-273 ◽  
Author(s):  
Sandra M. Dethlefsen ◽  
David Shepro ◽  
Patricia A. D'Amore

2013 ◽  
Vol 304 (1) ◽  
pp. C56-C67 ◽  
Author(s):  
James F. Markworth ◽  
David Cameron-Smith

Arachidonic acid (AA) is the metabolic precursor to a diverse range of downstream bioactive lipid mediators. A positive or negative influence of individual eicosanoid species [e.g., prostaglandins (PGs), leukotrienes, and hydroxyeicosatetraenoic acids] has been implicated in skeletal muscle cell growth and development. The collective role of AA-derived metabolites in physiological states of skeletal muscle growth/atrophy remains unclear. The present study aimed to determine the direct effect of free AA supplementation and subsequent eicosanoid biosynthesis on skeletal myocyte growth in vitro . C2C12 (mouse) skeletal myocytes induced to differentiate with supplemental AA exhibited dose-dependent increases in the size, myonuclear content, and protein accretion of developing myotubes, independent of changes in cell density or the rate/extent of myogenic differentiation. Nonselective (indomethacin) or cyclooxygenase 2 (COX-2)-selective (NS-398) nonsteroidal anti-inflammatory drugs blunted basal myogenesis, an effect that was amplified in the presence of supplemental free AA substrate. The stimulatory effects of AA persisted in preexisting myotubes via a COX-2-dependent (NS-389-sensitive) pathway, specifically implying dependency on downstream PG biosynthesis. AA-stimulated growth was associated with markedly increased secretion of PGF2α and PGE2; however, incubation of myocytes with PG-rich conditioned medium failed to mimic the effects of direct AA supplementation. In vitro AA supplementation stimulates PG release and skeletal muscle cell hypertrophy via a COX-2-dependent pathway.


1996 ◽  
Vol 271 (2) ◽  
pp. 883-888 ◽  
Author(s):  
Matthew N. Graber ◽  
Amparo Alfonso ◽  
Donald L. Gill
Keyword(s):  

1989 ◽  
Vol 44 (3) ◽  
pp. 186-191 ◽  
Author(s):  
Akira Fujimori ◽  
Masaharu Tsutsumi ◽  
Hajime Yamada ◽  
Masaaki Fukase ◽  
Takuo Fujita

1998 ◽  
Vol 118 (2) ◽  
pp. 159-164 ◽  
Author(s):  
Aaron Spingarn ◽  
Peter G. Sacks ◽  
Daniel Kelley ◽  
Andrew J. Dannenberg ◽  
Stimson P. Schantz

Products of arachidonic acid metabolism can influence normal and malignant cell growth. In vivo, inhibitors of arachidonic acid metabolism have been associated with inhibition of tumor growth, including head and neck squamous cell carcinoma (HNSCC). This has not been evaluated extensively in vitro in an HNSCC model. Therefore we investigated the effects of several arachidonic acid cascade inhibitors (AACIs) (indomethacin, curcumin, phenidone, nordihydroguaiaretic acid, 5,8,11,14-eicosatetraynoic acid, and 13- cisretinoic acid) on the growth of two HNSCC cell lines (MDA 886Ln and 1483). We found that AACIs caused dose-dependent growth inhibition of both cell lines. In an effort to inhibit HNSCC cell growth at lower concentrations of these drugs, we evaluated the effects of a variety of AACIs in combination with 13- cis retinoic acid. We observed synergistic growth inhibition when the drugs were used in all combinations, with the exception of indomethacin. These results suggest that AACIs may have some utility in the direct treatment of HNSCC, and a strategy combining 13- cis retinoic acid with other AACIs may prove to be even more effective.


Sign in / Sign up

Export Citation Format

Share Document